{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:59:54Z","timestamp":1793833194747,"version":"4.6.1"},"reference-count":59,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent data have implicated macrophage inflammatory protein-1\u03b1 (MIP-1\u03b1) in multiple myeloma (MM)-associated osteolysis. However, it is unclear whether the chemokine's effects are direct, to enhance osteolysis, or indirect and mediated through a reduction in tumor burden, or both. It is also unclear whether MIP-1\u03b1 requires other factors such as receptor activator of nuclear factor-\u03baB ligand (RANKL) for its effects on bone. In murine 5TGM1 (Radl) myeloma-bearing mice, administration of neutralizing anti-MIP-1\u03b1 antibodies reduced tumor load assessed by monoclonal paraprotein titers, prevented splenomegaly, limited development of osteolytic lesions, and concomitantly reduced tumor growth in bone. To determine the effects of MIP-1\u03b1 on bone in vivo, Chinese hamster ovary (CHO) cells secreting human MIP-1\u03b1 (CHO\/MIP-1\u03b1) were inoculated into athymic mice. Mice bearing intramuscular CHO\/MIP-1\u03b1 tumors developed lytic lesions at distant skeletal sites, which occurred earlier and were larger than those in mice with CHO\/empty vector (EV) tumors. When experimental metastases were induced via intracardiac inoculation, mice bearing CHO\/MIP-1\u03b1 tumors developed hypercalcemia and significantly more osteolytic lesions than mice bearing CHO\/EV tumors, with intramedullary CHO\/MIP-1\u03b1 tumors associated with significantly more tartrate-resistant acid phosphatase-positive (TRAP+) osteoclasts. Injection of recombinant MIP-1\u03b1 over calvariae of normal mice evoked a striking increase in osteoclast formation, an effect dependent on RANK\/RANKL signaling because MIP-1\u03b1 had no effect in RANK-\/- mice. Together, these results establish that MIP-1\u03b1 is sufficient to induce MM-like destructive lesions in bone in vivo. Because, in the 5TGM1 model, blockade of osteoclastic resorption in other situations does not decrease tumor burden, we conclude that MIP-1\u03b1 exerts a dual effect in myeloma, on osteoclasts, and tumor cells. (Blood. 2003;102:311-319)<\/jats:p>","DOI":"10.1182\/blood-2002-12-3905","type":"journal-article","created":{"date-parts":[[2003,3,25]],"date-time":"2003-03-25T01:50:10Z","timestamp":1048557010000},"page":"311-319","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":190,"title":["Dual effects of macrophage inflammatory protein-1\u03b1 on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease"],"prefix":"10.1182","volume":"102","author":[{"given":"Babatunde O.","family":"Oyajobi","sequence":"first","affiliation":[{"name":"From the Departments of Molecular Medicine and Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX; Molecular Therapeutics Division, CTRC (Cancer Therapy and Research Center) Institute for Drug Development, San Antonio, TX; and Laboratory of Cytokine Biology, The Picower Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Franchin","sequence":"additional","affiliation":[{"name":"From the Departments of Molecular Medicine and Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX; Molecular Therapeutics Division, CTRC (Cancer Therapy and Research Center) Institute for Drug Development, San Antonio, TX; and Laboratory of Cytokine Biology, The Picower Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Williams","sequence":"additional","affiliation":[{"name":"From the Departments of Molecular Medicine and Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX; Molecular Therapeutics Division, CTRC (Cancer Therapy and Research Center) Institute for Drug Development, San Antonio, TX; and Laboratory of Cytokine Biology, The Picower Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Pulkrabek","sequence":"additional","affiliation":[{"name":"From the Departments of Molecular Medicine and Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX; Molecular Therapeutics Division, CTRC (Cancer Therapy and Research Center) Institute for Drug Development, San Antonio, TX; and Laboratory of Cytokine Biology, The Picower Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Gupta","sequence":"additional","affiliation":[{"name":"From the Departments of Molecular Medicine and Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX; Molecular Therapeutics Division, CTRC (Cancer Therapy and Research Center) Institute for Drug Development, San Antonio, TX; and Laboratory of Cytokine Biology, The Picower Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Munoz","sequence":"additional","affiliation":[{"name":"From the Departments of Molecular Medicine and Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX; Molecular Therapeutics Division, CTRC (Cancer Therapy and Research Center) Institute for Drug Development, San Antonio, TX; and Laboratory of Cytokine Biology, The Picower Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Grubbs","sequence":"additional","affiliation":[{"name":"From the Departments of Molecular Medicine and Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX; Molecular Therapeutics Division, CTRC (Cancer Therapy and Research Center) Institute for Drug Development, San Antonio, TX; and Laboratory of Cytokine Biology, The Picower Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[{"name":"From the Departments of Molecular Medicine and Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX; Molecular Therapeutics Division, CTRC (Cancer Therapy and Research Center) Institute for Drug Development, San Antonio, TX; and Laboratory of Cytokine Biology, The Picower Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Chen","sequence":"additional","affiliation":[{"name":"From the Departments of Molecular Medicine and Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX; Molecular Therapeutics Division, CTRC (Cancer Therapy and Research Center) Institute for Drug Development, San Antonio, TX; and Laboratory of Cytokine Biology, The Picower Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sherry","sequence":"additional","affiliation":[{"name":"From the Departments of Molecular Medicine and Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX; Molecular Therapeutics Division, CTRC (Cancer Therapy and Research Center) Institute for Drug Development, San Antonio, TX; and Laboratory of Cytokine Biology, The Picower Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Mundy","sequence":"additional","affiliation":[{"name":"From the Departments of Molecular Medicine and Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), TX; Molecular Therapeutics Division, CTRC (Cancer Therapy and Research Center) Institute for Drug Development, San Antonio, TX; and Laboratory of Cytokine Biology, The Picower Institute for Medical Research, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217534634500_REF1","doi-asserted-by":"crossref","unstructured":"Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev.2002;13: 455-481.","DOI":"10.1016\/S1359-6101(02)00045-X"},{"key":"2020021217534634500_REF2","doi-asserted-by":"crossref","unstructured":"Gale LM, McColl SR. Chemokines: extracellular messengers for all occasions. Bioessays. 1999; 21: 17-28.","DOI":"10.1002\/(SICI)1521-1878(199901)21:1<17::AID-BIES3>3.0.CO;2-4"},{"key":"2020021217534634500_REF3","doi-asserted-by":"crossref","unstructured":"Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol.2001;2: 108-115.","DOI":"10.1038\/84209"},{"key":"2020021217534634500_REF4","doi-asserted-by":"crossref","unstructured":"Zlotnik A, Morales J, Hedrick JA. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol.1999;19: 1-47.","DOI":"10.1615\/CritRevImmunol.v19.i1.10"},{"key":"2020021217534634500_REF5","doi-asserted-by":"crossref","unstructured":"Sherry B, Tekamp-Olson P, Gallegos C, et al. Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1\u03b2. J Exp Med.1988; 168: 2251-2255.","DOI":"10.1084\/jem.168.6.2251"},{"key":"2020021217534634500_REF6","doi-asserted-by":"crossref","unstructured":"Wolpe SD, Davatelis G, Sherry B, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemotactic properties. J Exp Med.1988;167: 570-557.","DOI":"10.1084\/jem.167.2.570"},{"key":"2020021217534634500_REF7","doi-asserted-by":"crossref","unstructured":"Schall TJ, Bacon K, Camp RDR, Kaspari JW, Goeddel DV. Human macrophage inflammatory protein-1\u03b1 (MIP-1\u03b1) and MIP-1\u03b2 chemokines attract distinct populations of lymphocytes. J Exp Med.1993;177: 1821-1826.","DOI":"10.1084\/jem.177.6.1821"},{"key":"2020021217534634500_REF8","doi-asserted-by":"crossref","unstructured":"Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1\u03b1 and MIP-1\u03b2. Science.1993;260: 355-358.","DOI":"10.1126\/science.7682337"},{"key":"2020021217534634500_REF9","doi-asserted-by":"crossref","unstructured":"Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics, 2002. CA Cancer J Clin.2002;52: 23-45.","DOI":"10.3322\/canjclin.52.1.23"},{"key":"2020021217534634500_REF10","unstructured":"Mundy GR, Oyajobi BO. Pathophysiology of myeloma bone disease. In: Mundy GR, Rubens RD, eds. Cancer and the Skeleton. London: Martin Dunitz; 2000: 21-31."},{"key":"2020021217534634500_REF11","doi-asserted-by":"crossref","unstructured":"Choi S, Cruz JC, Craig J, Anderson J, Roodman GD, Alsina M. Macrophage inflammatory protein-1\u03b1 (MIP-1\u03b1) is a potential osteoclast stimulatory factor in myeloma. Blood.2000;96: 671-675.","DOI":"10.1182\/blood.V96.2.671"},{"key":"2020021217534634500_REF12","doi-asserted-by":"crossref","unstructured":"Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1\u03b1 and MIP-1\u03b2 in the development of osteolytic lesions in multiple myeloma. Blood.2002;100: 2195-2202.","DOI":"10.1182\/blood.V100.6.2195"},{"key":"2020021217534634500_REF13","doi-asserted-by":"crossref","unstructured":"Uneda S, Hata H, Matsuno F, et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol.2003;120: 53-55.","DOI":"10.1046\/j.1365-2141.2003.04040.x"},{"key":"2020021217534634500_REF14","doi-asserted-by":"crossref","unstructured":"Chauhan D, Auclair D, Robinson EK, et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene.2002;21: 1346-1358.","DOI":"10.1038\/sj.onc.1205205"},{"key":"2020021217534634500_REF15","doi-asserted-by":"crossref","unstructured":"Votta BJ, White JR, Dodds RA, et al. CK\u03b2-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues. J Cell Physiol.2000;183: 196-207.","DOI":"10.1002\/(SICI)1097-4652(200005)183:2<196::AID-JCP6>3.0.CO;2-8"},{"key":"2020021217534634500_REF16","doi-asserted-by":"crossref","unstructured":"Han J-H, Choi S-J, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1\u03b1 is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor \u03baB ligand. Blood.2001;97: 3349-3353.","DOI":"10.1182\/blood.V97.11.3349"},{"key":"2020021217534634500_REF17","doi-asserted-by":"crossref","unstructured":"Broxmeyer HE, Cooper S, Hangoc G, Gao J-L, Murphy PM. Dominant myelopoietic effector functions mediated by chemokine receptor CCR1. J Exp Med.1999;189: 1987-1992.","DOI":"10.1084\/jem.189.12.1987"},{"key":"2020021217534634500_REF18","doi-asserted-by":"crossref","unstructured":"Fuller K, Owens JM, Chambers TJ. Macrophage inflammatory protein-1\u03b1 and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts. J Immunol.1995;154: 6065-6072.","DOI":"10.4049\/jimmunol.154.11.6065"},{"key":"2020021217534634500_REF19","doi-asserted-by":"crossref","unstructured":"Scheven BAA, Milne JS, Hunter I, Robins SP. Macrophage inflammatory protein-1\u03b1 regulates preosteoclast differentiation in vitro. Biochem Biophys Res Commun.1999;254: 773-778.","DOI":"10.1006\/bbrc.1998.9909"},{"key":"2020021217534634500_REF20","doi-asserted-by":"crossref","unstructured":"Kukita T, Nakao J, Hamada F, et al. Recombinant LD78 protein, a member of the small cytokine family, enhances osteoclast differentiation in rat bone marrow culture system. Bone Miner.1992; 19: 215-223.","DOI":"10.1016\/0169-6009(92)90871-A"},{"key":"2020021217534634500_REF21","unstructured":"Kukita T, Nomiyama H, Ohmoto Y, et al. Macrophage inflammatory protein-1\u03b1 (LD78) expressed in human bone marrow: its role in regulation of hematopoesis and osteoclast recruitment. Lab Invest.1997;76: 399-406."},{"key":"2020021217534634500_REF22","doi-asserted-by":"crossref","unstructured":"Choi S-J, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1\u03b1 blocks bone destruction in a model of myeloma bone disease. J Clin Invest.2001;108: 1833-1841.","DOI":"10.1172\/JCI200113116"},{"key":"2020021217534634500_REF23","unstructured":"Radl J, Croese JW, Zurcher C, van den Enden-Vieveen MM, de Leeuw AM. Animal model of human disease: multiple myeloma. Am J Pathol.1988;132: 593-597."},{"key":"2020021217534634500_REF24","doi-asserted-by":"crossref","unstructured":"Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J.2000;1: 351-356.","DOI":"10.1038\/sj.thj.6200052"},{"key":"2020021217534634500_REF25","doi-asserted-by":"crossref","unstructured":"van den Akker TW, Radl J, Franken-Postma E, Hagemeijer A. Cytogenetic findings in mouse multiple myeloma and Waldenstrom's macro-globulinemia. Cancer Genet Cytogenet.1996;86: 156-161.","DOI":"10.1016\/0165-4608(95)00169-7"},{"key":"2020021217534634500_REF26","doi-asserted-by":"crossref","unstructured":"Zhu D, Van Arkel C, King CA, et al. Immunoglobulin Vh gene sequence analysis of spontaneous murine immunoglobulin-secreting B-cell tumors with clinical features of human disease. Immunology.1998;93: 162-170.","DOI":"10.1046\/j.1365-2567.1998.00428.x"},{"key":"2020021217534634500_REF27","doi-asserted-by":"crossref","unstructured":"Bakkus MH, Asosingh K, Vanderkerken K, et al. Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumor. Leukemia.2001;15: 1127-1132","DOI":"10.1038\/sj.leu.2402164"},{"key":"2020021217534634500_REF28","unstructured":"Oyajobi BO, Williams PJ, Gupta A, et al. A new syngeneic model of human multiple myeloma: in vivo green fluorescent protein (GFP)-imaging of skeletal and extramedullary tumors in mice [abstract]. Blood.2002;100: 171a."},{"key":"2020021217534634500_REF29","doi-asserted-by":"crossref","unstructured":"Dallas SL, Garrett IR, Oyajobi BO, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood.1999;93: 1697-1706.","DOI":"10.1182\/blood.V93.5.1697"},{"key":"2020021217534634500_REF30","doi-asserted-by":"crossref","unstructured":"Garrett IR, Dallas S, Radl J, Mundy GR. A murine model of myeloma bone disease. Bone.1997;20: 515-520.","DOI":"10.1016\/S8756-3282(97)00056-2"},{"key":"2020021217534634500_REF31","doi-asserted-by":"crossref","unstructured":"Schmidtmayerova H, Nottet HS, Nuovo G, et al. Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci U S A.1996;93: 700-704.","DOI":"10.1073\/pnas.93.2.700"},{"key":"2020021217534634500_REF32","doi-asserted-by":"crossref","unstructured":"Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev.1999;13: 2412-2424.","DOI":"10.1101\/gad.13.18.2412"},{"key":"2020021217534634500_REF33","doi-asserted-by":"crossref","unstructured":"Boyce BF, Aufdemorte TB, Garrett IR, Yates AJP, Mundy GR. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology.1989;125: 1142-1150.","DOI":"10.1210\/endo-125-3-1142"},{"key":"2020021217534634500_REF34","unstructured":"Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of a soluble receptor activator of nuclear factor \u03baB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res.2001;61: 2572-2578."},{"key":"2020021217534634500_REF35","doi-asserted-by":"crossref","unstructured":"Schwarz EM, Benz EB, Lu AP, et al. Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis. J Orthop Res.2000;18: 849-855.","DOI":"10.1002\/jor.1100180602"},{"key":"2020021217534634500_REF36","doi-asserted-by":"crossref","unstructured":"Mundy GR, Roodman GD, Bonewald LF, Oreffo RO, Boyce BF. Assays for bone resorption and bone formation. Methods Enzymol.1991;198: 502-510.","DOI":"10.1016\/0076-6879(91)98049-C"},{"key":"2020021217534634500_REF37","unstructured":"Matsuura N, Puzon-McLaughlin W, Irie A, Morikawa Y, Kakudo K, Takada Y. Induction of experimental bone metastasis by transfection of integrin \u03b14\u03b21 into tumor cells. Am J Pathol.1996; 148: 55-61."},{"key":"2020021217534634500_REF38","doi-asserted-by":"crossref","unstructured":"Pecheur I, Peyruchaud O, Serre CM, et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J.2002;16: 1266-1268.","DOI":"10.1096\/fj.01-0911fje"},{"key":"2020021217534634500_REF39","unstructured":"Guise TA, Chirgwin JM, Favarato G, Boyce BF, Mundy GR. Chinese hamster ovarian cells transfected with human parathyroid hormone-related protein cDNA cause hypercalcemia in nude mice. Lab Invest.1990;67: 477-485."},{"key":"2020021217534634500_REF40","doi-asserted-by":"crossref","unstructured":"Johnson RA, Boyce BF, Mundy GR, Roodman GD. Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology.1989;124: 1424-1427.","DOI":"10.1210\/endo-124-3-1424"},{"key":"2020021217534634500_REF41","doi-asserted-by":"crossref","unstructured":"de la Mata J, Uy HL, Guise TA, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest.1995;95: 2846-2852.","DOI":"10.1172\/JCI117990"},{"key":"2020021217534634500_REF42","unstructured":"Uy HL, Mundy GR, Boyce BF, et al. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res.1997;57: 3194-3199."},{"key":"2020021217534634500_REF43","unstructured":"Tanaka Y, Mine S, Hanagiri T, et al. Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells. Cancer Res.1998;58: 4138-4145."},{"key":"2020021217534634500_REF44","doi-asserted-by":"crossref","unstructured":"Michigami T, Shimizu N, Williams PJ, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and \u03b14\u03b21-integrin enhances production of osteoclast-stimulating activity. Blood.2000;96: 1953-1960.","DOI":"10.1182\/blood.V96.5.1953"},{"key":"2020021217534634500_REF45","doi-asserted-by":"crossref","unstructured":"Sanz-Rodriguez F, Teixido J. VLA-4-dependent myeloma cell adhesion. Leuk Lymphoma.2001; 41: 239-245.","DOI":"10.3109\/10428190109057979"},{"key":"2020021217534634500_REF46","unstructured":"Arendt BK, Miller AL, Arora T, Tschumper RC, Jelinek DF. Evidence for functional chemokine receptors on myeloma cells [abstract]. Blood.1998; 92: 100a."},{"key":"2020021217534634500_REF47","doi-asserted-by":"crossref","unstructured":"Lentzsch S, Gries M, Janz M, Bargou R, Do\u0308rken B, Mapara MY. Macrophage inflammatory protein 1-alpha (MIP-1\u03b1) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood.2003;101: 3568-3573.","DOI":"10.1182\/blood-2002-08-2383"},{"key":"2020021217534634500_REF48","doi-asserted-by":"crossref","unstructured":"Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res.2002;17: 1921-1925.","DOI":"10.1359\/jbmr.2002.17.11.1921"},{"key":"2020021217534634500_REF49","doi-asserted-by":"crossref","unstructured":"Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol.2002;20: 795-823.","DOI":"10.1146\/annurev.immunol.20.100301.064753"},{"key":"2020021217534634500_REF50","unstructured":"Oyajobi BO, Garrett IR, Williams PJ, Yoneda T, Anderson DM, Mundy GR. A soluble murine receptor activator of NF-\u03baB-human immunoglobulin fusion protein (RANK.Fc) inhibits bone resorption in a murine model of human multiple myeloma bone disease [abstract]. J Bone Miner Res.2000; 15: S176."},{"key":"2020021217534634500_REF51","doi-asserted-by":"crossref","unstructured":"Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A.2001;98: 11581-11586.","DOI":"10.1073\/pnas.201394498"},{"key":"2020021217534634500_REF52","doi-asserted-by":"crossref","unstructured":"Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol.2002;116: 278-290.","DOI":"10.1046\/j.1365-2141.2002.03257.x"},{"key":"2020021217534634500_REF53","unstructured":"Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res.2000;8: 681-703."},{"key":"2020021217534634500_REF54","doi-asserted-by":"crossref","unstructured":"Gooding RP, Bybee A, Cooke F, et al. Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia. Br J Haematol.1999;106: 669-681.","DOI":"10.1046\/j.1365-2141.1999.01602.x"},{"key":"2020021217534634500_REF55","doi-asserted-by":"crossref","unstructured":"Pellat-Deceunynk C, Amiot M, Bataille R, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood.1995;86: 4001-4002.","DOI":"10.1182\/blood.V86.10.4001.bloodjournal86104001"},{"key":"2020021217534634500_REF56","doi-asserted-by":"crossref","unstructured":"Carter CH. Chemokine receptor antagonism as an approach to anti-inflammatory therapy. Curr Opin Chem Biol.2002;6: 510-525.","DOI":"10.1016\/S1367-5931(02)00351-4"},{"key":"2020021217534634500_REF57","doi-asserted-by":"crossref","unstructured":"Proudfoot AE. Chemokine receptors: multi-faceted therapeutic targets. Nat Rev Immunol.2002; 2: 106-115.","DOI":"10.1038\/nri722"},{"key":"2020021217534634500_REF58","unstructured":"Oyajobi BO, Pulkrabek D, Williams P, et al. Macrophage inflammatory protein (MIP)-1\u03b1 stimulates osteoclast formation and bone resorption in vivo [abstract]. Blood.2000;14: 362a."},{"key":"2020021217534634500_REF59","unstructured":"Oyajobi BO, Williams PJ, Story B, Mundy GR. Myeloma bone disease and tumor burden reversed by neutralizing antibodies to macrophage inflammatory protein (MIP)-1\u03b1\/CCL3 in vivo [abstract]. J Bone Miner Res.2001;16: S192."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/1\/311\/1688548\/h81303000311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/1\/311\/1688548\/h81303000311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:19:37Z","timestamp":1682468377000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/1\/311\/16819\/Dual-effects-of-macrophage-inflammatory-protein1%CE%B1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-12-3905","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,1]]}}}